Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, RESUME-1 Study

Retrieved on: 2021-06-07 12:22:30

Tags for this article:

Click the tags to see associated articles and topics

Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, RESUME-1 Study. View article details on hiswai:

Excerpt

SAN DIEGO, June 7, 2021 /PRNewswire/ -- Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular ...

Article found on: www.prnewswire.com